hotspot -WSS

hotspot

author：entertainment 2025-10-02 21:36:35 - browse：83679

Humana’s Medicare Advantage enrollees got care in the hospital and physician clinics way more often than the company predicted at the end of 2023, forcing the health insurance giant on Thursday to drastically slash its profit projections for both 2023 and 2024.

Those higher medical costs will wipe away more than $775 million of profit that Humana had expected to bank for 2023. Humana also is “currently assessing the expected impact of emerging utilization trends on its 2024 outlook, which is anticipated to be material if current trends continue,” according to the company’s update to investors.

Humana’s bad news for Wall Street didn’t end there: The company said it appears it only added just 100,000 new Medicare Advantage members from the most recent enrollment period that ended last month — down from estimates that it would enroll anywhere from 325,000 to 435,000 people.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Biogen’s boardroom scandal saddles CEO with first crisis

entertainment

explore

WSS

Physicians and social media: If you see something, say something?

Indictment alleges Trump's ex

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

Montana youths win climate lawsuit against state for promoting fossil fuels

Biden administration begins canceling student loan debt for 804,000 borrowers

knowledge

hotspot

leisure time

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Treatments for cramps don't cut it. Why aren't there better options?

In Memoriam: Notable people who died in 2023

UnitedHealth increases loan offers after Change Healthcare outage

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

AstraZeneca to buy developer of next

Medical records are filled with copy

U.K. researchers warn about biases in medical devices, algorithms

Cancer drug shortages should be causing more outrage

Readout Newsletter: Bluebird, CVS, Contineum

hotspot

Nurses recount patients attacks

What to know about the judge who will handle the Trump case

Novo Nordisk touts Wegovy study, but still struggling with supply

After Optum profits sink, UnitedHealth makes changes

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Neuroscience’s long legacy of racism

entertainment

knowledge

explore

hotspot